Your browser doesn't support javascript.
loading
Lead Acetate-Injected Mice is an Animal Model for Extrapolation of Calcifying Response to Humans Due to Low Involvement of Bone Resorption.
Morikane, Shota; Ishida, Koichi; Ashizawa, Naoki; Taniguchi, Tetsuya; Matsubayashi, Masaya; Kurita, Naoki; Kobashi, Seiichi; Iwanaga, Takashi.
Afiliación
  • Morikane S; Research Laboratories 2, FUJI YAKUHIN CO., LTD., 636-1 Iidashinden, Nishi-ku, Saitama, Saitama Prefecture, 331-0068, Japan. s-morikane@fujiyakuhin.co.jp.
  • Ishida K; Research Laboratories 2, FUJI YAKUHIN CO., LTD., 636-1 Iidashinden, Nishi-ku, Saitama, Saitama Prefecture, 331-0068, Japan.
  • Ashizawa N; Research Laboratories 2, FUJI YAKUHIN CO., LTD., 636-1 Iidashinden, Nishi-ku, Saitama, Saitama Prefecture, 331-0068, Japan.
  • Taniguchi T; Research Laboratories 2, FUJI YAKUHIN CO., LTD., 636-1 Iidashinden, Nishi-ku, Saitama, Saitama Prefecture, 331-0068, Japan.
  • Matsubayashi M; Research Laboratories 2, FUJI YAKUHIN CO., LTD., 636-1 Iidashinden, Nishi-ku, Saitama, Saitama Prefecture, 331-0068, Japan.
  • Kurita N; Research Laboratories 2, FUJI YAKUHIN CO., LTD., 636-1 Iidashinden, Nishi-ku, Saitama, Saitama Prefecture, 331-0068, Japan.
  • Kobashi S; Research Laboratories 1, FUJI YAKUHIN CO., LTD., 3936-2 Sashiogi, Nishi-ku, Saitama, Saitama Prefecture, 331-0047, Japan.
  • Iwanaga T; Research Laboratories 2, FUJI YAKUHIN CO., LTD., 636-1 Iidashinden, Nishi-ku, Saitama, Saitama Prefecture, 331-0068, Japan.
Calcif Tissue Int ; 2024 Jul 01.
Article en En | MEDLINE | ID: mdl-38951181
ABSTRACT
Vascular calcification affects the prognosis of patients with renal failure. Bisphosphonates are regarded as candidate anti-calcifying drugs because of their inhibitory effects on both calcium-phosphate aggregation and bone resorption. However, calcification in well-known rodent models is dependent upon bone resorption accompanied by excessive bone turnover, making it difficult to estimate accurately the anti-calcifying potential of drugs. Therefore, models with low bone resorption are required to extrapolate anti-calcifying effects to humans. Three bisphosphonates (etidronate, alendronate, and FYB-931) were characterised for their inhibitory effects on bone resorption in vivo and calcium-phosphate aggregation estimated by calciprotein particle formation in vitro. Then, their effects were examined using two models inducing ectopic calcification the site where lead acetate was subcutaneously injected into mice and the transplanted, aorta obtained from a donor rat. The inhibitory effects of bisphosphonates on bone resorption and calcium-phosphate aggregation were alendronate > FYB-931 > etidronate and FYB-931 > alendronate = etidronate, respectively. In the lead acetate-induced model, calcification was most potently suppressed by FYB-931, followed by alendronate and etidronate. In the aorta-transplanted model, only FYB-931 suppressed calcification at a high dose. In both the models, no correlation was observed between calcification and bone resorption marker, tartrate-resistant acid phosphatase (TRACP). Results from the lead acetate-induced model showed that inhibitory potency against calcium-phosphate aggregation contributed to calcification inhibition. The two calcification models, especially the lead acetate-induced model, may be ideal for the extrapolation of calcifying response to humans because of calcium-phosphate aggregation rather than bone resorption as its mechanism.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Calcif Tissue Int Año: 2024 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Calcif Tissue Int Año: 2024 Tipo del documento: Article País de afiliación: Japón